Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis.
Adipogenesis
Breast cancer
Prediction
Recurrence
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
17
06
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Comprehensive analysis of clinical evidence for breast cancer adipogenesis with prognosis is lacking. This study aims to consolidate the latest evidence on the relationship between adipogenesis and breast cancer outcomes. Medline, Web of Science, Embase, Scopus, Clinicaltrials.gov, Cochrane library. A systematic review was conducted according to the PRISMA guidelines. Studies that reported the correlation between tumor adipogenesis and cancer recurrence or empirical pathological markers were included for meta-analysis. The standard reference for pathological markers determination was set as histopathological examination. The PROSPERO ID was CRD489135. Eleven studies were included in this systematic review and meta-analysis. Several adipogenesis biomarkers involved in the synthesis, elongation, and catabolism of fatty acids, such as FASN, Spot 14, pS6K1, lipin-1, PLIN2, Elovl6, and PPARγ, were identified as the potential biomarkers for predicting outcomes. Through meta-analysis, the predictive value of adipogenesis biomarkers for 5-year recurrence rate was calculated, with a pooled predictive risk ratio of 2.19 (95% CI: 1.11-4.34). In terms of empirical pathological markers, a negative correlation between adipogenesis biomarkers and ki-67 was observed (RR: 0.69, 95% CI: 0.61-0.79). However, no significant correlation was found between the adipogenesis and ER, PR, HER2, or p53 positivity. Biomarker of adipogenesis in breast cancer is a significant predictor of long-term recurrence, and this prediction is independent of HR, HER2, and ki-67. The diverse roles of adipogenesis in different breast cancer subtypes highlight the need for further research to uncover specific biomarkers that can used for diagnosis and prediction. PROSPERO ID: CRD489135.
Sections du résumé
BACKGROUND
BACKGROUND
Comprehensive analysis of clinical evidence for breast cancer adipogenesis with prognosis is lacking. This study aims to consolidate the latest evidence on the relationship between adipogenesis and breast cancer outcomes.
DATA SOURCES
METHODS
Medline, Web of Science, Embase, Scopus, Clinicaltrials.gov, Cochrane library.
METHODS
METHODS
A systematic review was conducted according to the PRISMA guidelines. Studies that reported the correlation between tumor adipogenesis and cancer recurrence or empirical pathological markers were included for meta-analysis. The standard reference for pathological markers determination was set as histopathological examination. The PROSPERO ID was CRD489135.
RESULTS
RESULTS
Eleven studies were included in this systematic review and meta-analysis. Several adipogenesis biomarkers involved in the synthesis, elongation, and catabolism of fatty acids, such as FASN, Spot 14, pS6K1, lipin-1, PLIN2, Elovl6, and PPARγ, were identified as the potential biomarkers for predicting outcomes. Through meta-analysis, the predictive value of adipogenesis biomarkers for 5-year recurrence rate was calculated, with a pooled predictive risk ratio of 2.19 (95% CI: 1.11-4.34). In terms of empirical pathological markers, a negative correlation between adipogenesis biomarkers and ki-67 was observed (RR: 0.69, 95% CI: 0.61-0.79). However, no significant correlation was found between the adipogenesis and ER, PR, HER2, or p53 positivity.
CONCLUSIONS
CONCLUSIONS
Biomarker of adipogenesis in breast cancer is a significant predictor of long-term recurrence, and this prediction is independent of HR, HER2, and ki-67. The diverse roles of adipogenesis in different breast cancer subtypes highlight the need for further research to uncover specific biomarkers that can used for diagnosis and prediction.
PROTOCOL REGISTRATION
BACKGROUND
PROSPERO ID: CRD489135.
Identifiants
pubmed: 39333940
doi: 10.1186/s12885-024-12931-1
pii: 10.1186/s12885-024-12931-1
doi:
Substances chimiques
Biomarkers, Tumor
0
Perilipin-2
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181Informations de copyright
© 2024. The Author(s).
Références
Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708–28. https://doi.org/10.1016/j.cell.2023.01.040 .
doi: 10.1016/j.cell.2023.01.040
pubmed: 36931265
Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog Lipid Res. 2018;69:11–20.
doi: 10.1016/j.plipres.2017.11.002
pubmed: 29175445
An X, et al. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer. 2018;18:331. https://doi.org/10.1186/s12885-018-4170-7 .
doi: 10.1186/s12885-018-4170-7
pubmed: 29587760
pmcid: 5870251
Liu Y, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the nurses’ Health Study. Breast Cancer Res Treat. 2011;129:175–84. https://doi.org/10.1007/s10549-011-1432-3 .
doi: 10.1007/s10549-011-1432-3
pubmed: 21390493
pmcid: 3640508
Xu XL, et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat. 2013;139:329–39. https://doi.org/10.1007/s10549-013-2563-5 .
doi: 10.1007/s10549-013-2563-5
pubmed: 23670132
Goodwin PJ, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30:19–26. https://doi.org/10.1200/JCO.2010.33.0068 .
doi: 10.1200/JCO.2010.33.0068
pubmed: 22147742
Chen Y, et al. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study. Ann Transl Med. 2022;10:93. https://doi.org/10.21037/atm-21-6924 .
doi: 10.21037/atm-21-6924
pubmed: 35282081
pmcid: 8848398
Abubakar M, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol. 2019;32:1244–56. https://doi.org/10.1038/s41379-019-0270-4 .
doi: 10.1038/s41379-019-0270-4
pubmed: 30976105
pmcid: 6731159
Couldrey C, et al. Adipose tissue: a vital in vivo role in mammary gland development but not differentiation. Dev Dyn. 2002;223:459–68. https://doi.org/10.1002/dvdy.10065 .
doi: 10.1002/dvdy.10065
pubmed: 11921335
Wu Q, et al. Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol. 2019;12:95. https://doi.org/10.1186/s13045-019-0778-6 .
doi: 10.1186/s13045-019-0778-6
pubmed: 31500658
pmcid: 6734503
Neville MC, Medina D, Monks J, Hovey RC. The mammary fat pad. J Mammary Gland Biol Neoplasia. 1998;3:109–16. https://doi.org/10.1023/a:1018786604818 .
doi: 10.1023/a:1018786604818
pubmed: 10819521
Abduljabbar R, et al. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Res Treat. 2015;150:511–22. https://doi.org/10.1007/s10549-015-3348-9 .
doi: 10.1007/s10549-015-3348-9
pubmed: 25794775
Oshi M, et al. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep. 2021;11:12541. https://doi.org/10.1038/s41598-021-91897-7 .
doi: 10.1038/s41598-021-91897-7
pubmed: 34131208
pmcid: 8206113
Song L, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020;11(1):5842. https://doi.org/10.1038/s41467-020-19694-w .
Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science. 2002;296:1046–9. https://doi.org/10.1126/science.1067431 .
doi: 10.1126/science.1067431
pubmed: 12004111
pmcid: 2788989
Jansen S, et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci. 2005;118:3081–9. https://doi.org/10.1242/jcs.02438 .
doi: 10.1242/jcs.02438
pubmed: 15985467
Lee JO, et al. Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep. 2016;6:18923. https://doi.org/10.1038/srep18923 .
doi: 10.1038/srep18923
pubmed: 26729407
pmcid: 4700449
Strong AL, et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res. 2015;17. https://doi.org/10.1186/s13058-015-0622-z .
Anurag M, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-negative breast Cancer. Cancer Discov. 2022;12:2586–605. https://doi.org/10.1158/2159-8290.CD-22-0200 .
doi: 10.1158/2159-8290.CD-22-0200
pubmed: 36001024
pmcid: 9627136
Choi J, et al. Predicting the benefit of adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients with phosphorylated s6k1 expression status. J Breast Cancer. 2020;23(1):10–9.
doi: 10.4048/jbc.2020.23.e5
pubmed: 32140266
Duong MN, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 2015;17. https://doi.org/10.1186/s13058-015-0569-0 .
Cui YF, et al. NADPH accumulation is responsible for apoptosis in breast cancer cells induced by fatty acid synthase inhibition. Oncotarget. 2017;8:32576–85. https://doi.org/10.18632/oncotarget.15936 .
doi: 10.18632/oncotarget.15936
pubmed: 28427229
pmcid: 5464810
Dinarvand N, et al. Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene. J Cell Physiol. 2020;235:5835–46. https://doi.org/10.1002/jcp.29523 .
doi: 10.1002/jcp.29523
pubmed: 31970786
Feng YH, et al. Elovl6 is a poor prognostic predictor in breast cancer. Oncol Lett. 2016;12:207–12. https://doi.org/10.3892/ol.2016.4587 .
doi: 10.3892/ol.2016.4587
pubmed: 27347126
pmcid: 4907155
Lucenay KS, et al. Cyclin e associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Res. 2016;76(8):2406–18.
doi: 10.1158/0008-5472.CAN-15-1646
pubmed: 26928812
pmcid: 4873469
Park CS, et al. pS6K1 as an efficacy marker of gnrh agonist with premenopausal breast cancer. Endocr Connections. 2019;8(7):863–9.
doi: 10.1530/EC-19-0101
Wells WA, et al. Expression of Spot 14 (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat. 2006;98:231–40. https://doi.org/10.1007/s10549-005-9154-z .
doi: 10.1007/s10549-005-9154-z
pubmed: 16552628
Yoshikawa K, et al. Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer. Biomed Rep. 2022;16. https://doi.org/10.3892/mco.2022.2513 .
Zhang D, et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteom. 2005;4:1686–96. https://doi.org/10.1074/mcp.M400221-MCP200 .
doi: 10.1074/mcp.M400221-MCP200
Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27–9.
pubmed: 13032945
Feng WW, Kurokawa M. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer. Cancer Drug Resist. 2020;3:1–17. https://doi.org/10.20517/cdr.2019.100 .
doi: 10.20517/cdr.2019.100
pubmed: 32226926
pmcid: 7100881
Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202–8. https://doi.org/10.1016/s0899-9007(99)00266-x .
doi: 10.1016/s0899-9007(99)00266-x
pubmed: 10705076
Liu B, et al. Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1153076. https://doi.org/10.3389/fonc.2023.1153076 .
doi: 10.3389/fonc.2023.1153076
pubmed: 37124526
pmcid: 10135304
Wang YX, et al. Friend or foe: multiple roles of adipose tissue in cancer formation and progression. J Cell Physiol. 2019;234:21436–49. https://doi.org/10.1002/jcp.28776 .
doi: 10.1002/jcp.28776
pubmed: 31054175
Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358–65. https://doi.org/10.1097/01.mco.0000232894.28674.30 .
doi: 10.1097/01.mco.0000232894.28674.30
pubmed: 16778563
Naik A, Decock J. Lactate Metabolism and Immune Modulation in breast Cancer: a focused review on Triple negative breast tumors. Front Oncol. 2020;10:598626. https://doi.org/10.3389/fonc.2020.598626 .
doi: 10.3389/fonc.2020.598626
pubmed: 33324565
pmcid: 7725706
Dias AS, Almeida CR, Helguero LA, Duarte IF. Metabolic crosstalk in the breast cancer microenvironment. Eur J Cancer. 2019;121:154–71. https://doi.org/10.1016/j.ejca.2019.09.002 .
doi: 10.1016/j.ejca.2019.09.002
pubmed: 31581056
Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res. 2003;63:132–9.
pubmed: 12517789
Jin Q, et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010;12:R96. https://doi.org/10.1186/bcr2777 .
doi: 10.1186/bcr2777
pubmed: 21080941
pmcid: 3046439
Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K. Enhanced thermogenesis in Triple-negative breast Cancer is Associated with Pro-tumor Immune Microenvironment. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13112559 .
Giro-Perafita A, et al. Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. Oncotarget. 2017;8:74391–405. https://doi.org/10.18632/oncotarget.20152 .
doi: 10.18632/oncotarget.20152
pubmed: 29088795
pmcid: 5650350